PD-L1 blockade: rejuvenating T cells in CLL

Arnon P. Kater; Gerritje J. W. van der Windt

doi:https://doi.org/10.1182/blood-2015-05-638338

PD-L1 blockade: rejuvenating T cells in CLL

Arnon P. Kater, Gerritje J. W. van der Windt

Research output: Contribution to journal › Editorial › Academic › peer-review

5 Citations (Scopus)

Abstract

In this issue of Blood, there are 2 articles by McClanahan et al describing T-cell defects in murine chronic lymphocytic leukemia (CLL) in the context of aging which show that therapeutic targeting of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling prevents immune dysfunction and leukemia development.(1,2)

Original language	English
Pages (from-to)	126-128
Journal	Blood
Volume	126
Issue number	2
DOIs	https://doi.org/10.1182/blood-2015-05-638338
Publication status	Published - 2015

Access to Document

https://doi.org/10.1182/blood-2015-05-638338

Cite this

@article{f331fd1f1c7844baa1ee13c98e17dcf9,

title = "PD-L1 blockade: rejuvenating T cells in CLL",

abstract = "In this issue of Blood, there are 2 articles by McClanahan et al describing T-cell defects in murine chronic lymphocytic leukemia (CLL) in the context of aging which show that therapeutic targeting of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling prevents immune dysfunction and leukemia development.(1,2)",

author = "Kater, {Arnon P.} and {van der Windt}, {Gerritje J. W.}",

year = "2015",

doi = "https://doi.org/10.1182/blood-2015-05-638338",

language = "English",

volume = "126",

pages = "126--128",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "2",

}

TY - JOUR

T1 - PD-L1 blockade: rejuvenating T cells in CLL

AU - Kater, Arnon P.

AU - van der Windt, Gerritje J. W.

PY - 2015

Y1 - 2015

N2 - In this issue of Blood, there are 2 articles by McClanahan et al describing T-cell defects in murine chronic lymphocytic leukemia (CLL) in the context of aging which show that therapeutic targeting of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling prevents immune dysfunction and leukemia development.(1,2)

AB - In this issue of Blood, there are 2 articles by McClanahan et al describing T-cell defects in murine chronic lymphocytic leukemia (CLL) in the context of aging which show that therapeutic targeting of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling prevents immune dysfunction and leukemia development.(1,2)

U2 - https://doi.org/10.1182/blood-2015-05-638338

DO - https://doi.org/10.1182/blood-2015-05-638338

M3 - Editorial

C2 - 26160184

SN - 0006-4971

VL - 126

SP - 126

EP - 128

JO - Blood

JF - Blood

IS - 2

ER -